{"analyses":[{"ciLowerLimit":"-0.065","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.082","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.038","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.82","paramType":"Slope","paramValue":"0.009","statisticalComment":"The treatment effect was determined by testing the significance of the group by time interaction in GEE using a one degree-of-freedom (df) test.","statisticalMethod":"Generalized Estimating Equation (GEE)"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.067","value":"1.728"},{"groupId":"OG001","spread":"0.071","value":"1.732"}]}],"title":"BL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.048","value":"1.642"},{"groupId":"OG001","spread":"0.069","value":"1.769"}]}],"title":"6m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.065","value":"1.723"},{"groupId":"OG001","spread":"0.079","value":"1.722"}]}],"title":"12m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.063","value":"1.732"},{"groupId":"OG001","spread":"0.081","value":"1.732"}]}],"title":"18m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.063","value":"1.603"},{"groupId":"OG001","spread":"0.074","value":"1.64"}]}],"title":"24m"}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"description":"Ratio of peak velocity blood flow from left ventricular relaxation in early diastole (E wave) to peak velocity flow in late diastole caused by atrial contraction (A wave). \"Number\" shown for Unit of Measure refers to this ratio. Normal: \\>1. Impaired: \\<1. The mean is reported by arm at each timepoint with corresponding standard errors.","dispersionType":"Standard Error","groups":[{"description":"Patients received Carvedilol PO delivered at 6.25 mg twice daily (for a total dose of 12.5 mg per day) for 24 months.","id":"OG000","title":"Arm I (Carvedilol)"},{"description":"Patients received Placebo PO delivered at 6.25 mg twice daily (for a total dose of 12.5 mg per day) for 24 months.","id":"OG001","title":"Arm II (Placebo)"}],"paramType":"MEAN","populationDescription":"We excluded 31 participants who did not have a second time point assessment of echocardiography, resulting in 151 analyzable participants.","reportingStatus":"POSTED","timeFrame":"Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation","title":"Average Peak Early Atrial Divided by Peak Late Atrial Velocities","type":"SECONDARY","unitOfMeasure":"ratio"}